Insulin pump therapy is perceived as liberating, but to many it can imply a sense of the diabetes made visible
DOI:
https://doi.org/10.1002/edn.246Keywords:
diabetes mellitus type 1, insulin infusion system, quality of life, treatment satisfaction, qualitative researchAbstract
AbstractThis study describes how adults with type 1 diabetes experience the transition from multiple daily injections (MDI) to continuous subcutaneous insulin infusion (CSII or ‘insulin pump’). The study is based on interviews in focus groups, with 11 persons with type 1 diabetes who had had CSII for at least one year, which were analysed using qualitative content analysis. The analysis resulted in three categories: life and health; involvement of others; and technology dependence. Participants’ experiences are summarised in the theme ‘CSII is perceived as liberating, but also implies a sense of the diabetes made visible’. The transition resulted in changed life and health with greater freedom and flexibility, particularly in meal situations. The participants felt that their blood glucose was easier to control. Those around them reacted with curiosity, but some participants felt compelled to tell others that they had diabetes since the pump could be seen or heard. The participants found that coping with CSII in daily life was easier and more comfortable than they had expected. However, having to constantly be prepared for technical failure was experienced as cumbersome. All participants indicated that they were satisfied with their treatment and recommended it to others. Transition to CSII may be experienced as liberating, but might also imply a sense of the diabetes made visible. The results can be used in clinical practice, when advising about CSII. Being aware of both positive and negative experiences with CSII can contribute to better care for those already being treated with CSII.
Downloads
References
The Swedish National Diabetes Registry. NDR report 2011. (https://www.ndr.nu/; accessed 16 June 2014).
De Vries JH, Snoek FJ, Kostense PJ, et at. A randomised trial of continuous subcuta-neous insulin infusion system and intensive injection therapy in type 1 diabetes for patients with longstanding poor glycemic control. Diabetes Care 2002;25:2074–2080.
Bruttomesso D, Crazzolara D, Maran A, et al. In type 1 diabetic patients with good gly-caemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabetic Medicine 2008; 25:326–332.
Hoogma RP, Hammond PJ, Gomis R, et at. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabetic Medicine 2005;23:141–147.
Linkeschova R, Raoul M, Bott U, et aL Less severe hypoglycaemia, better metabolic con-trol, and improved quality of life in type 1 diabetes mellitus with continuous subcuta-neous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetic Medicine 2002;19:746–751.
Misso ML, Egbets KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus (Review): The Cochrane collaboration 2010;1:CD005103.
Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:1–6.
Garmo A, Garmo H, Arnlöv J, Leksell J. Long-term treatment effects of insulin pump therapy. Practical Diabetes 2011; 28:295–299.
Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin lispro. Diabetes Care 2001;24:1722–1727.
Barnard KD, Skinner TC. Qualitative study into quality of life issues surrounding insulin pump use in type 1 diabetes. Practical Diabetes 2007;24:143–148.
Garmo A, Hornsten A, Leksell J. "The pump was a savior for me". Patients experiences of insulin pump therapy. Diabetic Medicine 2013;30:717–723.
Ritholtz MD, Smaldone A, Lee J, et aL Perceptions of psychosocial factors and the insulin pump. Diabetes Care 2007; 30:549–554.
Todres L, Keen S, Kerr D. Continuous sub-cutaneous insulin infusion in type 1 diabetes: patient experiences of "living with a machine". Diabetic Medicine 2010; 27:1201–1204.
Graneheim UH, Lundman B. Qualitative content analysis in nursing research: con-cepts, procedures and measures to achieve trustworthiness. Nurse Education Today 2004;24:105–112.
Scheidegger U, Allemann S, Scheidegger K, Diem P. Continuous subcutaneous insulin infusion therapy: effects on quality of life. Swiss Medical Weekly 2007; 137:476–482.
Bolli G, Kerr D, Reena T, Torlone E, Sola-Gazagnes A, Vitacolonna E, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes. Diabetes Care 2009; 32:1170–1176.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Copyright © 2014 FEND.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
